Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma.

ABSTRACT:

Background

Systemic chemotherapy or chemoradiation therapy has proven to be effective in treating advanced biliary tract carcinoma (BTC). However, its efficacy in the adjuvant setting remains controversial. Therefore, this study aimed to determine the prognostic significance of genomic biomarkers in resected BTC and their potential role in stratifying patients for adjuvant treatment.

Methods

We retrospectively reviewed 113 BTC patients who underwent curative-intent surgery and had available tumor sequencing data. Disease-free survival (DFS) was the primary outcome examined and univariate analysis was used to identify gene mutations with prognostic value. Favorable and unfavoratble gene subsets were distinguished from the selected genes through grouping, respectively. Multiva

SUBMITTER: Li Y 

PROVIDER: S-EPMC10469713 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature